CureGenetics Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Suzhou Jiangsu China

Primary Industry

Biotechnology

About

Based in Suzhou, China and established in 2016, CureGenetics is a bio-pharmacy company that developed gene and cells therapy drugs for genetic diseases and tumors, taking the technology of gene edition, virus delivery, macromolecule modification. The company has established cooperation with BI to develop vector delivery for treat liver diseases. The company provides gene edition, vector delivery, and molecular optimization. The gene edition can achieve design of specific gene editing tools for vitro cell therapy and in vivo gene therapy, optimization tools for editing genetic information in the nucleus of specific tissues, and high-performance and safe developed tools for packaged by AAV virus. The virus vector delivery can achieve CRISPR platform to synchronize AAV virus packaging, and AAV virus production platform reducing costs. The molecular optimization includes targeted optimization for screened AAV virus, design optimization for molecules of cell therapy, and innovative design for protein drug molecules. The company plans to accelerate the clinical development of blood and tumor cell therapy products, and to promote the development and international cooperation of innovative serotype screening and gene editing products.

Current Investors

Qiming Venture Partners, Tsing Song Capital, Oriza Holdings

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Healthcare, Oncology/Cancer Treatment, Pharmaceuticals

Verticals

HealthTech

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.